2012-09-01
EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion
Publication
Publication
Neuro-Oncology , Volume 14 - Issue 9 p. 1125- 1135
Eph/ephrin signaling has been implicated in various types of key cancer-enhancing processes, like migration, proliferation, and angiogenesis. In medulloblastoma, invading tumor cells characteristically lead to early recurrence and a decreased prognosis. Based on kinaseactivity profiling data published recently, we hypothesized a key role for the Eph/ephrin signaling system in medulloblastoma invasion. In primary medulloblastoma samples, a significantly higher expression of EphB2 and the ligand ephrin-B1 was observed compared with normal cerebellum. Furthermore, medulloblastoma cell lines showed high expression of EphA2, EphB2, and EphB4. Stimulation of medulloblastoma cells with ephrin-B1 resulted in a marked decrease in in vitro cell adhesion and an increase in the invasion capacity of cells expressing high levels of EphB2. The cell lines that showed an ephrin-B1-induced phenotype possessed increased levels of phosphorylated EphB2 and, to a lesser extent, EphB4 after stimulation. Knockdown of EphB2 expression by short hairpin RNA completely abolished ephrin ligand-induced effects on adhesion and migration. Analysis of signal transduction identified p38, Erk, and mTOR as downstream signaling mediators potentially inducing the ephrin-B1 phenotype. In conclusion, the observed deregulation of Eph/ephrin expression in medulloblastoma enhances the invasive phenotype, suggesting a potential role in local tumor cell invasion and the formation of metastases.
Additional Metadata | |
---|---|
, , , , , | |
doi.org/10.1093/neuonc/nos130, hdl.handle.net/1765/63866 | |
Neuro-Oncology | |
Organisation | Department of Gastroenterology & Hepatology |
Sikkema, A. H., den Dunnen, W., Hulleman, E., van Vuurden, D., Garcia-Manero, G., Yang, H., … de Bont, E. (2012). EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro-Oncology, 14(9), 1125–1135. doi:10.1093/neuonc/nos130 |